BioSante will immediately assume all manufacturing, distribution and marketing responsibilities for Elestrin. Elestrin is a fast-drying gel formulation of estradiol, the same estrogen produced naturally in women, and is FDA approved for the treatment of hot flashes in menopausal women.
Stephen Simes, BioSante’s president & CEO, said: “We are pleased to reacquire Elestrin since Nycomed concentrates on dermatology products and neither Bradley nor Nycomed to date were successful in marketing Elestrin.”
In addition to Elestrin which BioSante developed through the FDA approval in 2006, BioSante is actively developing LibiGel (testosterone gel) for the treatment of female sexual dysfunction in menopausal women, specifically hypoactive sexual desire disorder.